KemPharm Signs a Definitive Agreement with Orphazyme to Acquire Arimoclomol for the Treatment of Niemann-Pick Disease Type C
Shots:
- KemPharm to acquire Orphazyme assets including Arimoclomol for $12.8M in cash and assumed liabilities estimated to ~$5.2M. The transaction is expected to close on or before June 1, 2022
- The acquisition will expand KemPharm’s CNS disease development pipeline to advance & commercialize novel treatments for rare CNS conditions including KP1077 in IH. KemPharm plans to refile Arimoclomol’s NDA for NPC with the US FDA as early as Q1’23
- Orphazyme's EAP provides Arimoclomol to NPC patients in the US, France & Germany. Arimoclomol has received ODD for NPC in the US & EU while FTD, BTD & RPDD from the US FDA for NPC & will be eligible for a pediatric PRV if it approved in the US
Ref: Globenewswire | Image: KemPharm
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
